Thursday, December 13, 2018

Akero Therapeutics Gets $70M

San Francisco-based Akero Therapeutics, a biotechnology startup developing treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, said this week that it has raised $70M in a Series B funding round. The funding was led by Janus Henderson Investors, and also included Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, and LifeSci Venture Partners, plus Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures. The company said the funds go towaards its lead clinical candidate, AKR-001. More information »